#### Nina R. Schwalbe MPH 55 White Street NYC NY nschwalbe@sparkstreetadvisors.org

# EMPLOYMENT

# Spark Street Advisors

# Founder and Chief Executive Officer, New York

Principal at a global advisory firm of 10 people worldwide that advises C-suite executives and supports development of evidenced-based strategy, policy and leadership in the health and social sectors. Past and present clients include CEPI, the Bill and Melinda Gates Foundation, GAVI, the Global Fund to Fight AIDS. TB and Malaria. Fondation Botnar. ELMA Philanthropies. Children's Investment Fund, UNICEF, WHO, Stop TB, the World Bank, the Global Financing Facility, among others.

# USAID

# Director, Vaccine Access and Delivery Initiative

Designed and led the US Government program to deliver 1B doses of Pfizer vaccine through the COVAX facility. Managed contracts with Pfizer and distribution of \$500M of funding to USAID missions in countries for health systems support and \$350M in distribution to partners.

# UNICEF

# Acting Chief of Health, Associate Director, Program Division

Led UNICEF's global health program with staff of 100+ people in New York HQ and offices in 120+ countries. Oversaw programs on polio and immunization, health systems, maternal and child health, and emergencies with an overall commitment of appr. \$2B to health-related programs organization-wide. Developed multisector UNICEF Strategy for Health 2016-2030. Managed donors and partnerships. Responsible for fundraising. Member of the design team for the World Bank's Global Financing Facility for Reproductive, Material and Newborn Health.

# Principal Advisor, Health, New York

Focused on improving program integration and managing for results. Advised senior leadership on strategies, special projects, and engagement with partners. Represented UNICEF at senior level with governments, donors and partners, including in design of the World Bank -led Global Financing Facility. Developed new agency-wide initiatives on non-communicable diseases and adolescents. Responsible for budgets and staffing, with direct oversight of 50+ people.

# GAVI, the vaccine alliance

# Managing Director, Policy & Performance, Gavi Secretariat, Geneva Deputy Executive Secretary, UNICEF, Geneva

Member of executive team of organization focusing on distribution of vaccines and strengthening health systems in 73 countries. Responsible for strategic planning, policy development, monitoring and evaluation, performance and risk management, vaccine supply and procurement, and financial oversight of funding to WHO and UNICEF. Achievements included development of organizational strategy and business plan, investment prioritization mechanism, pneumococcal Advance Market Commitment, demand forecasting platform, performance management and risk assessment systems, supply and procurement strategy, country eligibility, evaluation, donation and gender policies. Managed relationships with industry and contracts with UN partners.

# Global Alliance for TB Drug Development

# **Director of Policy, New York**

Responsible for public policy and resource mobilization at a not-for-profit drug company. Managed relations with developing countries, OECD governments, UN bodies and the G8 regarding adoption, procurement and distribution of new drugs. Analyzed supply chain, adoption pathways, and drug markets in key countries. Raised over \$150M from public and private donors.

#### 2005-2007

#### 2014

# 2016 to pres.

# 2015

2021 (July) - 2022 (Feb)

# 2009-2014 2007-2008

# **Open Society Institute/Soros Foundation**

# Director, Public Health Programs, New York

Designed and directed a global public health program for the worldwide network of Soros Foundations. Activities included grant-making and implementing operational programs in the areas of tuberculosis, tobacco control, HIV/AIDS, reproductive health, community engagement, health systems strengthening, workforce development, information systems, quality improvement, and health policy. Co-author of the first Global Plan to Stop TB and founding Board member of the Stop TB Partnership. Oversaw activities in 26 countries (CEE/FSU, West Africa, Southern Africa, Asia).

# Director, Public Health Program, Moscow

Established and directed \$100M initiative for the Soros Foundation. Program focused on public health in Russia through support of the NGOs and professional associations, prevention programs on HIV/AIDS and multidrug resistant TB, and promotion of evidence-based medicine and public health education. Achievements included establishment of harm reduction as federal policy, introduction of school-based health education, and development of post graduate public health education. Other focus areas included reproductive health, palliative care, and geriatrics.

# AVSC International

# Program Manager, New York

Managed reproductive health programs and country offices in Russia, Ukraine and Moldova. Funding sources included the US and the UK governments and the United Nations.

# Country Program Advisor, Ekaterinburg, Russia

Established and directed the Russia country office. Implemented a USAID-funded reproductive health project and managed study on sexually transmitted diseases.

# **Population Council**

# Program Officer, Bangkok, Thailand

Conducted reproductive health operations research in Thailand, Vietnam, and Laos. Developed "Safe Motherhood" Situation Analysis. Organized fellowship program for health professionals from Vietnam.

#### Graduate Research Assistant, New York

Evaluated large-scale international family planning programs and reviewed findings from family planning research over the past two decades.

# Ban Vinai Refugee Camp – Thailand

Administrative Secretary

# United Nations High Commissioner for Refugees (UNHCR)

Assisted with administration of community survey, mass immunization campaign, food distribution and protection issues in camp of 40,000 on the Thai/Lao border.

# Volunteer

# COERR

Volunteered with program for mentally and physically disabled refugees and conducted training of trainers program for English language instructors.

# **EDUCATION**

#### Doctor of Philosophy, Faculty of Health Sciences University of Witwatersrand, Johannesburg

Candidate for PhD with a focus on access to medicines. Expected spring 2024.

# Master of Public Health,

#### 2000-2004

1998-2000

1997-1998

1994-1996

# 1993-1994

#### 1992-1993

1989-1990

#### 1989

1993

2021-present

# Columbia University School of Public Health, New York Focused on maternal and child health with significant course work in epidemiology. Recipient of Foreign

# Language and Area Studies Fellowship (FLAS) and graduate research assistantship.

# Certificate for Advanced Study of the Soviet Union, Harriman Institute, Columbia University, New York

Harvard/Radcliffe Colleges, Cambridge, Massachusetts AB with honors in Russian and Soviet Studies. Radcliffe 4th Class Marshall. Aloin-Beale Award. Education for Action (E4A) Award.

# APPOINTMENTS, ELECTED POSITIONS, BOARD MEMBERSHIPS, COMMITTEES AND AWARDS

# Current appointments

Bachelor of Arts,

<i>Current appointments</i> Commissioner, Gender and Health, The Lancet Principal Visiting Fellow, UNU-IIGH, Kuala Lumper, Malaysia Adjunct Assistant Professor, Columbia University, NY, NY Peer reviewer, U.K. Medical Research Council, Lancet, BMJ, Nature Life Member, Council on Foreign Relations, New York, NY	2020 – present 2019 – present 2018 – present 2017 - present 2006 – present
<i>Current elected positions</i> Secretary, Class of 1988, Harvard-Radcliffe Colleges, Cambridge, MA President, Board of Directors, 55 White Street Association, NY, NY	2019 – present 2018 – present
Previous boards Commissioner, Women's Refugee Committee, New York, NY Chair, Gavi Board Evaluation Advisory Committee, Geneva, CH Member, Gavi Board Evaluation Advisory Committee, Geneva, CH Board Member, Open Health Institute, Moscow Constituency Board Member, Global Fund for AIDS, TB and Malaria Board Member, European Observatory of Health Care Reform Board Member, Stop TB Coordinating Board, Geneva Board Member, AIDS Foundation East West (AFEW), Netherlands Board Member, International Gay Lesbian Human Rights Coalition, NY Board Member, AESOP, Moscow	2014 - 2023 2019 - 2021 2017 - 2018 2003 - 2006 2000 - 2005 2000 - 2005 2001 - 2006 2001 - 2007 2001 - 2004 1994 - 1996
Previous committees and awards Co-lead, WHO COVID-19 Working Group on Indirect Effects of COVID-19 and Educational Institutions, Geneva, CH Member, Alumnae Board, Brearley School, New York, NY Associate Editor, BioMed Central Health Services Research, London Member, Advisory Committee, Global Task Force on Expanded Access to Cancer Care and Control, Harvard Univ., Cambridge. MA Lecturer, Advanced Course of Vaccinology, WHO Member, Advisory Committee, Initiative for Vaccine Research, WHO Faculty, Department of Family Health, Mailman School of Public Health Feranc Boyan Memorial Lecture, European Public Health Association Member, Forecasting Working Group, Center for Global Dev., DC Co-chair, "Retooling" Task Force, Stop TB Partnership, Geneva Participant, World Economic Forum, Davos, Switzerland Francis Riker Davis Award, Brearley School, New York, NY Advisor, Public Health Watch, Open Society Institute, New York, NY Juror, Development Marketplace, World Bank, Washington, DC Peer Reviewer, Health, World Bank, Washington	2020 - 2022 2015 - 2018 2012 - 2017 2009 - 2013 2008 - 2013 2006 - 2008 2006 2006 - 2007 2006 - 2007 2005 2004 2004 - 2008 2003 2002 - 2005

1993

1988-89

Committee Member, UN Millennium Development Project, Task Force V	2002 - 2005
ECOSOC representative, Open Society Institute, NY	2002 - 2004
Speaker, World Economic Forum Regional Meeting, Alma Aty	2001
Intern, East-West Institute, New York, NY	1987
Intern, Allen & Company, New York, NY	1986

# SELECTED PUBLICATIONS

#### GENERAL AUDIENCE

Schwalbe N. We cannot give up on the global pandemic treaty. Financial Times. August 31, 2023.

Schwalbe N., Hannon E. We need a pandemic treaty — but it must hold nations accountable. *Washington Post.* December 5, 2022

Schwalbe N. Why we need a new compact on vaccines. Financial Times. May 30, 2022.

Schwalbe N. First Opinion: Strengthening Gavi is a way forward for global vaccine equity. *Stat.* May 9, 2022.

Schwalbe N, Lehtimaki S. The World Should Treat Pandemics Like It Treats Chemical Weapons. *Foreign Policy*. Published online April 14, 2021.

Schwalbe N. Why Are We Closing Schools? The Atlantic. Published online November 19, 2020.

Schwalbe N, Hupert N. Models, Math, and COVID-19: A Public Health Response. *Think Global Health*. Published online April 21, 2020.

Schwalbe N. We could be vastly overestimating the death rate for COVID-19. Here's why. *World Economic Forum*. Published online April 4, 2020.

Schwalbe N. GAVI working to reduce vaccine prices. Development Today. July 8, 2011.

Schwalbe N, Ignatius HR. New Drugs for TB: Past time to deliver. Global AIDS Link. 2006.

Schwalbe N. TB is largest killer of those with HIV. The Wall Street Journal. July 18, 2002.

# PROFESSIONAL AND PEER REVIEW JOURNALS

Nassiri-Ansari T, Schwalbe N, Lehtimaki S. From Lemming to Leader: Moving beyond Gross Domestic Product (GDP) to bring health financing assistance into the 21st century. *PLOS Global Public Health*. (Forthcoming)

Schwalbe N, Nunes MC, Cutland C, Wahl B, Reidpath D. Assessing New York City's COVID-19 Vaccine Rollout Strategy: A Case for Risk-Informed Distribution. *J Urban Health*. Published online 05 April 2024. doi.org/10.1007/s11524-024-00853-z.

Schwalbe N, Hannon E, Gilby L, Lehtimaki S. Governance provisions in the WHO Pandemic Agreement draft. *The Lancet*. Published online March 22, 2024. doi.org/10.1016/S0140-6736(24)00585-3.

Phelan AL, Schwalbe N. Getting in Formation: WHO Constitutional Heads of Power and the Pandemic Agreement. *Opinio Juris*. March 13, 2024.

Meier BM, Finch A, Schwalbe N. Shaping Global Health Law through United Nations Governance: The UN High-Level Meeting on Pandemic Prevention, Preparedness and Response. *Journal of Law, Medicine & Ethics*. 2023;51(4):972-978. doi:10.1017/jme.2024.14.

Schwalbe N, Hannon E, Lehtimaki S. The new pandemic treaty: Are we in safer hands? Probably not. *BMJ.* 2024 Feb 22;384:q477. doi: 10.1136/bmj.q477. PMID: 38387977.

Hannon E, Schwalbe N, Lehtimaki S. WHO member states are negotiating a pandemic treaty. But will countries follow the new rules? *Bulletin of Atomic Scientists*. February 15, 2022.

Lehtimaki S, Hannon E, Hanbali L, Soltan DF, Peek K, Nassiri-Ansari T, Schwalbe N. Where there is a will, there is a way: independent assessment of member state compliance with the pandemic agreement. *The Lancet.* doi.org/10.1016/S2214-109X(23)00515-6. Epub 2023 Nov 17.

Hanbali L, Hannon E, Lehtimaki S, McNab C, Schwalbe N. Independent monitoring and the new pandemic agreement. *BMJ Global Health*. 2023;8:e013348. doi:10.1136/ bmjgh-2023-013348.

Aars OK, Schwalbe N. Bold moves for vaccine manufacturing equity. *The Lancet.* Volume 402, Issue 10404, September 02, 2023.

Lal A, Schwalbe N. Primary health care: a cornerstone of pandemic prevention, preparedness, response, and recovery. *The Lancet*. Volume 401, Issue 10391, May 19, 2023.

Hanbali L, Lehtimaki S, Hannon, E, McNab C, Schwalbe N. Independent monitoring for the pandemic accord: a non-negotiable provision. *The Lancet.* Volume 401, Issue 10376, January 31, 2023.

Schwalbe N, Hanbali L, Nunes MC, Lehtimaki S. Use of financial incentives to increase adult vaccination coverage: A narrative review of lessons learned from COVID-19 and other adult vaccination efforts. Vaccine X. 2022 Dec;12:100225. doi: 10.1016/j.jvacx.2022.100225. Epub 2022 Oct 6. PMID: 36217357; PMCID: PMC9535879.

Hannon E, Hanbali L, Lehtimaki S, and Schwalbe N. Why we still need a pandemic treaty. *The Lancet Global Health.* Volume 10, Issue 9, 1 September 2022.

Nassiri-Ansari T, Atuhebwe, P, Siki Ayisi A, Goulding, S, Johri, M, Allotey P, and Schwalbe N. Shifting gender barriers in immunisation in the COVID-19 pandemic response and beyond. *The Lancet.* Volume 400, Issue 10345, 2–8 July 2022.

Viner R, Russell S, Saulle R, Stansfield C, Croker H, Packer J, Nicholls D, Goddings AL, Bonell C, Hudson L, Hope S, Ward J, Schwalbe N, Morgan A, Minozzi S. School Closures During Social Lockdown and Mental Health, Health Behaviors, and Well-being Among Children and Adolescents During the First COVID-19 Wave: A Systematic Review. *JAMA Pediatrics*. Published online January 18, 2022.

Oliver K, Raut A, Pierre S, Silvera L, Boulos A, Gale A, Baum A, Chory A, David NJ, D'Souza D, Freeman A, Goytia C, Hamilton A, Horowitz C, Islam N, Jeavons J, Knudson J, Li S, Lupi J, Martin R, Maru S, Nabeel I, Pimenova D, Romanoff A, Rusanov S, Schwalbe N, Vangeepuram N, Vreeman R, Masci J, Maru D. Factors associated with COVID-19 vaccine receipt at two integrated healthcare systems in New York City: a cross-sectional study of healthcare workers. *BMJ Open.* 2022;12:e05341.

Aars OK, Clark M, Schwalbe N. Increasing efficiency in vaccine production: A primer for change. *Vaccine: X*. 2021;8(100104).

Lehtimaki S, Martic J, Wahl B, Foster KT, Schwalbe N. Evidence on Digital Mental Health Interventions for Adolescents and Young People: Systematic Overview. *JMIR Mental Health*. 2021;8(4):e25847.

Schwalbe N. The US now has vaccines, but no strategy on how to use them to defeat coronavirus. The

BMJ Opinion. Published online December 17, 2020.

Schwalbe N, Wahl B, Song J, Lehtimaki S. Data Sharing and Global Public Health: Defining What We Mean by Data. *Front Digit Health*. Published online December 14, 2020.

Schwalbe N, Lehtimaki S, Gutiérrez JP. COVID-19: Rethinking Risk. *Lancet Glob Health*. 2020;8(8):e974-e975.

Kettler H, Lehtimaki S, Schwalbe N. Accelerating Access to Medicines in a Changing World. *Bulletin of the World Health Organization*. 2020;98:641-643.

Schwalbe N, Lehtimaki S, Gutiérrez JP. Non Communicable Diseases and COVID-19: A Perfect Storm. *The BMJ Opinion*. Published online June 10, 2020.

Schwalbe N, Wahl B. Artificial Intelligence and the Future of Global Health. *Lancet*. 2020;395(10236):1579-1586.

Schwalbe N, Crowley S, Lehtimaki S, Allotey P. Deaths from COVID-19 Could be the Tip of the Iceberg. *The BMJ Opinion.* Published online May 20, 2020.

Wahl B, Lehtimaki S, Germann S, Schwalbe N. Expanding the Use of Community Health Workers in Urban Settings: A Potential Strategy for Progress Towards Universal Health Coverage. *Health Policy and Planning*. 2020;35(1):91-101.

Nguyen A, Schwalbe N. Apples and oranges? Can second generation vaccines become as low cost as generic medicines? *Vaccine*. 2019;37(22):2910-2914.

Wahl B, Cossy-Gantner A, Germann S, Schwalbe N. Artificial intelligence (AI) and global health: how can AI contribute to health in resource-poor settings? *BMJ Global Health*. 2018;3(4):e000798.

Schwalbe N, Fearon J. Time's up for journal gender bias. The Lancet. 2018;391(10140):P2601-2602. =

Schwalbe N. Global health: generation men. The Lancet. 2017;390(10096):P733.

Brumana L, Arroyo A, Schwalbe N, Lehtimaki S. Maternal and child health services and an integrated, life-cycle approach to the prevention of non-communicable diseases. *BMJ Glob Health*. 2017;2:e000295.

Chandrasekharan S, Amin T, Kim J, Furrer E, Matterson AC, Schwalbe N, Nguyen A. Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers. *Vaccine*. 2015;33(46):6366-6370.

Lee LA, Franzel L, Atwell J, Datta SD, Friberg IK, Goldie SJ, Reef SE, Schwalbe N, Simons E, Strebel PM, Sweet S, Suraratdecha C, Tam Y, Vynnycky E, Walker N, Walker DG, Hansen PM. The estimated mortality impact of vaccinations forecast to be administered during 2011-2020 in 73 countries supported by the GAVI Alliance. *Vaccine*. 2013;31(2):B61-B72.

Hanson CM, Furrer E, Schwalbe N, Berkley S. Prediction of immunization performance. *The Lancet*. 2013;381(9864):P249-350.

Cernuschi T, Furrer E, McAdams S, Jones A, Fihman J, Schwalbe N. *Pneumococcal Advance Market Commitment: Lessons Learnt on Disease and Design Choices and Processes.* GAVI Alliance; 2011.

Wells W, Konduri N, Chen C, Lee D, Ignatius HR, Gardiner E, Schwalbe N. Implications of the current tuberculosis treatment landscape for future regimen change. *Int J Tuberc Lung Dis.* 2011;15(6):746-753.

Saxenian H, Cornejo S, Thorien K, Hecht R, Schwalbe N. An Analysis Of How The GAVI Alliance And

Low- And Middle-Income Countries Can Share Costs Of New Vaccines. Health Affairs. 2011;30(6).

Wells WA, Konduri N, Chen C, David L, Ignatius HR, Gardiner E, Schwalbe N. Tuberculosis regimen change in high- burden countries. *Int J Tuberc Lung Dis.* 2011;15(31):425.

Cernuschi T, Furrer E, Schwalbe N, Jones A, Berndt ER, McAdams S. Advance market commitment for pneumococcal vaccines: putting theory into practice. *Bulletin of the World Health Organization*. 2011;89:913-918.

Levin A, Fang A, Hansen PM, Pyle D, Ousmane D, Schwalbe N. A global health partnership's use of time-limited support to catalyze health practice change: the case of GAVI's injection safety support. *PLoS One*. 2010;5(9):e12986.

Schwalbe N, El-Ziq I. GAVI's Advance Market Commitment. The Lancet. 2010;375(9715):P638-639.

Global Alliance for TB Drug Development, Schwalbe N, Ignatius HR, Wells WA, Patel N, Forcellina A, DiCola L, Chen C. *New TB Regimens: What Countries Want. The Value Proposition of Existing and New First-Line Regimens for Drug-Susceptible Tuberculosis.*; 2009.

Schwalbe N, Wells WA, Geaneotes A, Forcellina A, Lee MG, DiCola L, Ignatius HR, Walker C, Raafat T, Patel N. Estimating the market for tuberculosis drugs in industrialized and developing nations. *Int J Tuberc Lung Dis.* 2008;12(10):1173-1181.

Kruk M, Schwalbe N, Aguiar C. Timing of default from tuberculosis treatment: a systematic review of the literature. *Tropical Medicine and International Health*. 2008;13(5):703-712.

Kruk M, Schwalbe N. The relation between intermittent dosing and adherence: preliminary insights. *Clin Ther*. 2006;28(12):1989-1995.

McKee M, Gilmore AB, Schwalbe N. International co-operation and health. Part I: issues and concepts. *Journal of Epidemiology and Community Health*. 2005;59(8).

McKee M, Gilmore AB, Schwalbe N. International co-operation and health. Part 2: making a difference. *Journal of Epidemiology and Community Health*. 2005;59:737-739.

McKee M, Bernd R, Schwalbe N. The European Union, South Eastern Europe and the wider European neighborhood. *Europealth*. 2005;10(3):7-9.

Danishevski K, Balabanova D, McKee M, Nolte E, Schwalbe N, Vasilieva N. Inequalities in birth outcomes in Russia: evidence from Tula oblast. *Paediatric and Perinatal Epidemiology*. 2005;19:352-359.

Bernd R, Schwalbe N. Health in South Eastern Europe. Eurohealth. 2005;10(3):6.

Bernd R, Schwalbe N, McKee M. Health in South Eastern Europe: a troubled past, an uncertain future. *Bulletin of the World Health Organization*. 2004;82:539-546.

Schwalbe N, Harrington P. HIV and Tuberculosis in the former Soviet Union. *The Lancet.* 2003;360(1).

Burrows D, Holmes D, Schwalbe N. Drug use injects HIV/AIDS into former Soviet Union. *Global AIDS Link (Global Health Council)*. 2002;72:12-13.

# WHITE PAPERS, MONOGRAPHS AND BOOK CHAPTERS

Spark Street Advisors, UNU-IIGH. Independent Monitoring for the Pandemic Accord: A Proposal for

Action. United Nations University International Institute for Global Health; 2023.

Hanbali L, Hannon E, Lehtimaki S, McNab C, Schwalbe N. *Independent Monitoring Mechanism for the Pandemic Accord: Accountability for a safer world.* United Nations University International Institute for Global Health; 2022.

Allotey P, Binagwaho A, Lehtimaki S, Liwanag HJ, Rhule E, Schwalbe N. Access to Education During Public Health Emergencies: Keep Schools Open. Think20 Italy; September 2021.

Lehtimaki S, Reidy A, Nishtar K, Darehshori S, Painter A, Schwalbe N. *Independent Review and Investigation Mechanisms to Prevent Future Pandemics: A Proposed Way Forward*. United Nations University International Institute for Global Health; 2021.

Yamey G, Kraus J, Fewer S, Schwalbe N. *Intensified Multilateral Cooperation on Global Public Goods for Health: Three Opportunities for Collective Action*. The Center for Policy Impact in Global Health; 2018.

Nguyen A, Furrer E, Schwalbe N. *Market Shaping: Strategic Considerations for a Healthy Vaccine Marketplace*. GAVI Alliance; 2011.

Cornejo S, Schwalbe N, Tanguy J. Building Ownership and Sustainability: Country Co-Financing of Vaccines. GAVI Alliance; 2011.

Schwalbe N, Lazarus J, Adeyi O. HIV/AIDS and tuberculosis control in post-Soviet Union countries. In: *Health Systems and the Challenge of Communicable Diseases: Experiences from Europe and Latin America*. Open University Press; 2008.

Millennium Development Project Task Force V. *Investing in Strategies to Reverse the Global Incidence of TB*. United Nations Development Programme; 2005.

London School of Hygiene and Tropical Medicine, Open Society Institute, UK Department for International Development, United Nations Children's Fund Regional office for CEE/CIS and Baltic States. *Healing the Crisis: A Prescription for Public Health Action in South Eastern Europe*. Open Society Institute; 2003.

Schwalbe N, Mehta M, Beattie K, Barone M. Factors affecting the safe provision of IUDs: A service delivery perspective from Ekaterinburg, Russia. *AVSC International*. Published online 1998.

Sloan N, Quimby C, Winikoff B, Schwalbe N. Guidelines and instruments for a situation analysis of obstetric services. *Population Council*. Published online 1995.

LANGUAGES Native English; Proficient Russian; Conversational French.